Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma

Oncology Times - OT Broadcasts from the iPad Archives by Oncology Times

Findings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching early to immune checkpoint inhibition appeared to bring better rates of overall...View more